Preventing TB: Recent Research Results and Novel Short Course Therapy for LTBI
|
|
- Terence Paul
- 6 years ago
- Views:
Transcription
1 Preventing TB: Recent Research Results and Novel Short Course Therapy for LTBI Constance A. Benson, M.D. Professor of Medicine Director, UCSD AntiViral Research Unit PI, CD4 Collaborative HIV Clinical Trials Unit University of California, San Diego
2 Introduction Revised WHO guidelines for LTBI treatment in HIV Evidence base for revisions Obstacles to uptake Impact of antiretroviral therapy on TB prevention Short course alternatives for treatment of LTBI Clinical trials of novel short course regimens TBTC Study 26 ACTG A5279 Where do we go from here?
3 Risk of Developing Active TB Latent TB Infection (LTBI) Any positive test for LTBI (TST or IGRA) in a person with no clinical, laboratory or radiographic evidence of active TB Risk of active TB in immunocompetent adults: 12.9 per 1,000 person-years (~10% lifetime risk) Highest risk within 2-3 years after index exposure Risk in HIV-infected individuals: After index exposure: 30-40% within 3-6 months Risk of reactivation TB in persons with LTBI (+TST) per 1,000 person-years (3-16% per year)
4 Current Approaches to Tuberculosis Prevention The three (or four) I s Intensified case finding identifying those with active TB, appropriate treatment to reduce infectiousness Isoniazid prophylaxis for treatment of latent TB infection (LTBI) Infection control Initiation of ART (for HIV-infected persons)
5 Treatment of Latent TB Infection in HIV Infected Persons Review of 12 RCTs of TB preventive therapy in HIV (N=8,578; any anti-tb drugs vs placebo) 32% in incidence of active TB (RR 0.68; 95% CI ); 62% for TST+ pts (RR 0.38; 95% CI ) Reduced mortality: INH alone vs. placebo among those with TST+ (RR 0.74, 95% CI ) INH+RIF vs. placebo regardless of TST (RR 0.69, 95% CI ) Efficacy similar for all regimens but effect wanes over time Akolo C, et al. The Cochrane Collaboration; 2010
6 Revised WHO Guidelines for TB Prevention in Resource-Constrained Settings with High TB Incidence & Transmission Adults and adolescents living with HIV, who have an unknown or positive TST and among whom active TB disease has been ruled out should receive at least 36 months of IPT. IPT should be given to such individuals regardless of whether or not they are receiving ART. IPT should also be given irrespective of the degree of immunosuppression, history of previous TB treatment, and pregnancy. (Conditional recommendation, low quality of evidence) WHO, 2015
7 Meta-Analysis of Three Randomized Controlled Trials Compared outcomes in pts receiving continuous IPT vs. 6-months IPT or equivalent Irrespective of TST = unknown TST status Reduction in mortality for TST-positive (RR 0.50; 95% CI: ) Significantly more grade 3 or 4 AEs in the continuous IPT group in one study; non-significant increase in the others Adherence 6-mos IPT 83.8% vs. 60.4% for 36-mos in one study Incidence of Active TB Irrespective of TST Continuous IPT 6-month IPT RR (95% CI) 41/1509 (2.7%) 78/1659 (4.7%) 0.62 ( ) Positive TST 0.51 ( )
8 Meta-Analysis of Three Randomized Controlled Trials Den Boon S, et al. AIDS 2016; 30:
9 Thibela Study: Durability of IPT 9H significantly reduced TB incidence rate only while participants were on the drug Churchyard G, et al. NEJM 2014
10 Cumulative TB Incidence After 36 Months of IPT Samandari T, et al. AIDS 2015:351-9
11 THRio Study: Durability of IPT in Medium TB Prevalence Setting 6.52/100 PY ahr 0.17; 95% CI /100 PY Golub JE, et al. Clin Infect Dis 2015; 60:639-45
12 Obstacles to Uptake of IPT Poor adherence to long duration of IPT Maybe worse with 36 months IPT Insufficient healthcare infrastructure to support DOT or adherence monitoring Risk of toxicity associated with INH Concerns about the inability to effectively rule out subclinical active TB Durability of IPT in high TB prevalence settings
13 Impact of Antiretroviral Therapy on Risk of TB
14 Impact of Antiretroviral Therapy on Tuberculosis
15 Impact of ART on TB Incidence Suthar AB, et al. PLoS Med 2012; 9:e
16 START: Immediate vs Deferred Therapy for ART-Naive Patients International, randomized trial Study closed by DSMB following interim analysis HIV-positive, ART-naive adults with CD4+ cell count > 500 cells/mm 3 (N = 4685) Immediate ART ART initiated immediately following randomization (n = 2326) Deferred ART Deferred until CD4+ cell count 350 cells/mm 3, AIDS, or event requiring ART (n = 2359) Primary composite endpoint (target = 213) Serious AIDS or death from AIDS Serious non-aids events and death not attributable to AIDS CVD, ESRD, decompensated liver disease, non-aids defining cancers INSIGHT START Study Group. N Engl J Med. 2015;373: Lundgren J, et al. IAS Abstract MOSY0302.
17 Impact of ART on Tuberculosis INSIGHT START Study Group. N Engl J Med. 2015;373: Lundgren J, et al. IAS Abstract MOSY0302.
18 Interaction of ART and IPT in Reducing TB Incidence Samandari T, et al. Lancet 2011; 377:
19 Cumulative Probability of Death or Severe HIV-Related Illness (%) TEMPRANO: Immediate vs Deferred ART and IPT for African Patients Mo Probability, % Deferred ART 14.1 Deferred ART + IPT 8.8 Immediate ART 7.4 Immediate ART + IPT Mos From Randomization TEMPRANO ANRS Study Group. N Engl J Med. 2015;373:
20 Impact of ART and CD4 Count on TB Risk TB Rate Baseline CD4 > 500/mm 3 Early ART/No IPT Early ART/IPT Deferred ART/No IPT Deferred ART/IPT Total TB TB Incidence Baseline CD4 < 500/mm 3 TB Incidence
21 Can LTBI Treatment Be Shortened in Those on ART?
22 Short Course Treatment of LTBI in HIV Infection Daily RIF/PZA x 2 mos vs 12-month IPT (Gordin F, et al. JAMA; 2000) N=1,583 HIV-infected, TST+ persons (70% in U.S.) Regimen completion: INH-69% vs. RIF/PZA-80% No differences in TB rates, HIV disease progression or death RIF/PZA Higher discontinuation rates for AEs 2 studies with intermittent RIF/PZA regimens (Zambia, Haiti) overall TB rates higher vs. INH
23 Rifapentine Long-acting rifamycin-s derivative; inhibits DNA-dependent RNA polymerase T 1/2 ~5x longer than RIF; broader tissue distribution and higher tissue levels than RIF More potent against MTB in vitro (MIC 0.06 vs 0.25 mg/l); greater sterilizing activity in murine models of active TB treatment Treatment-related adverse effects: GI upset/nausea, lightheadedness, dry mouth, diarrhea, headache
24 Rifapentine-INH Weekly for 3 Months Weekly Twice weekly Martinson NA, et al. NEJM 2011; 365:11-20
25 TBTC Study 26: Study Design Randomized, open-label study design Treatment arms: Once weekly rifapentine + INH x 12 weeks (DOT) Daily INH x 9 months (self-administered) N=8,053 enrolled Children 2-11 and HIV-infected persons continued enrollment until 12/15/10 33 months of followup from date of enrollment Primary endpoint: Culture confirmed TB in persons > 18 y.o. Culture confirmed or clinical TB in persons < 18 y.o.
26 TBTC Study 26: TB Event Rates Event rates after 33 months of followup from time of randomization; non-inferiority margin (delta) = 0.75% Sterling TR, et al. NEJM 2011; 365:
27 TBTC Study 26: 3HP more effective than 9H? 9H treatment completion 69% 3HP treatment completion 82%
28 TBTC Study 26: 3HP better tolerated than 9H Adverse Events 3HP N=3986 9H N=3745 P-value Permanent D/C due to AE 4.9% 3.7% Hepatotoxicity 0.4% 2.7% < Permanent D/C due to Hepatotoxicity Permanent D/C due to Hypersensitivity 0.3% 2.0% < % 0.4% < Sterling TR, et al. NEJM 2011; 365:
29 Study 26: Conclusions Weekly RPT + INH x 3 months was safe and effective in reducing TB rate comparable to daily INH x 9 months in low-medium TB prevalence settings (95% C.I. of difference 0.08%; margin = 0.75%) TB incidence rate (0.19%) lower vs. 9H (0.35%) but did not reach statistical significance Treatment completion rate (82%) was significantly higher vs. 9H (69.5%) Treatment tolerability 3HP better than for 9H
30 Study 26 Results: HIV-Infected Pts Time to TB by Arm (MITT)
31 Study 26 Results: HIV-Infected Pts
32 Shorter Courses of Rifapentine/INH for Treatment of LTBI? Mouse model 10-wk old female BALBc mice Low dose aerosol challenge with virulent strain of MTB (stable lung infection < 10 4 CFU) Quantitative spleen CFU counts in tissue Daily RPT 10 mg/kg/d x 8 wks Daily RPT/INH x 4 wks more effective than RIF/INH and indistinguishable from RIF/PZA x 4 wks Zhang T, et al. Am J Resp Crit Care Med; 2009
33 ACTG 5279: Ultra-Short Course Daily RPT/INH Prospective, multicenter, randomized trial Study design N=3,000 HIV-infected patients +TST/+IGRA or Reside in TB endemic area where TB rate > 60 cases/100,000 population/year Randomized 1:1 to daily RPT (~10 mg/kg) + INH 300 mg x 4 weeks or daily INH 300 mg x 9 months ART allowed after 4 wks (NRTIs, NNRTIs only) Followed for 3 years after last patient enrolled Results 4 th quarter 2017
34 TB Preventive Therapy Studies
35 Proposed Study Schema Single Cycle vs Annual Cycles of HP 6 months INH HIV+, any CD4 cell count, on/starting ART 1 cycle INH/RPT Observation = Randomization N=3378 Annual cycles INH/RPT regardless of CD4 Annual cycles INH/RPT regardless of CD4 Annual cycles INH/RPT regardless of CD4 Month 0 Month 12 Month 24 Month 36
36 Where do we go from here? One size may not fit all Different uptake and durability depending on TB prevalence settings Poor uptake, limited durability of 6-9 months IPT in medium-high TB prevalence settings Poor uptake of 36P, limited durability in high prevalence settings 3HP not tested in higher TB prevalence settings Effect of ART at higher CD4 on 3HP, 36P efficacy and durability TST, IGRA testing
37 Questions?
Hot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs
Slide 1 Hot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs Constance A. Benson, M.D. Professor of Medicine Division of Infectious Diseases University of California, San Diego
More informationTB Prevention in PLHIV: Options Other Than Isoniazid. Johns Hopkins Center for Tuberculosis. Research. Richard E. Chaisson, MD
TB Prevention in PLHIV: Options Other Than Isoniazid Johns Hopkins Center for Tuberculosis Richard E. Chaisson, MD Research Johns Hopkins University Center for Tuberculosis Research Consortium to Respond
More informationThe role of ART and IPT in TB prevention: Latest updates
The role of ART and IPT in TB prevention: Latest updates Richard E. Chaisson, MD Center for Tuberculosis Research Johns Hopkins University Consortium to Respond Effectively To the AIDS-TB Epidemic (CREATE)
More informationOngoing research on LTBI treatment and IMPAACT4TB
Ongoing research on LTBI treatment and IMPAACT4TB GJ Churchyard MBBCh (WITS), FCP (SA), FRCP (Edin), MMED (Int Med), PhD (WITS) 1 st September 2017 Who and when? PLHIV Household contacts High risk communities
More informationTB prevention studies in PLHIV: recent updates and what can they tell us for the future?
TB prevention studies in PLHIV: recent updates and what can they tell us for the future? Richard E. Chaisson, MD Center for AIDS Research Center for TB Research Johns Hopkins University TB/HIV Working
More informationNon-rifampin rifamycins in TB/HIV
Non-rifampin rifamycins in TB/HIV Richard E. Chaisson, MD Johns Hopkins University Center for TB Research Consortium to Respond Effectively to the AIDS-TB Epidemic Rifamycins for TB Inhibit bacterial DNA-dependent
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationSharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center
TB Infection Diagnostics and Treatment Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention 1 Curry International
More informationINH Prophylaxis Therapy (IPT) should NOT be implemented for all HIV patients in the Asia Pacific
INH Prophylaxis Therapy (IPT) should NOT be implemented for all HIV patients in the Asia Pacific Thuy Le, MD DPhil Duke University School of Medicine, USA Oxford University Clinical Research Unit Hospital
More informationScreening and management of latent TB Infection Gerry Davies
Screening and management of latent TB Infection Gerry Davies Reader in Infection Pharmacology Institutes of Infection and Global Health & Translational Medicine HIV Scientific Meeting Liverpool 21st July
More informationWhat Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ
What Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ Outline Combination prevention for HIV Approaches to TB prevention Individual Household/key
More informationContact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
More informationWhat more is required to use rifamycin regimens to prevent TB in people living with HIV in resource constrained settings?
What more is required to use rifamycin regimens to prevent TB in people living with HIV in resource constrained settings? Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI
More informationBackground. The global burden of latent M. tuberculosis. More than 2 billion people infected
What s New in Treatment tof LTBI Alfred Lardizabal, MD November 17, 2011 Washington, D.C. Background The global burden of latent M. tuberculosis infection is enormous More than 2 billion people infected
More informationThe Role of Rifampin for the Treatment of Latent TB Infection. Introduction. Introduction
The Role of Rifampin for the Treatment of Latent TB Infection March 26, 2008 Alfred A. Lardizabal, MD Associate Professor of Medicine New Jersey Medical School Global Tuberculosis institute Treatment of
More informationIsoniazid Prevention Therapy for HIV Positive Patients
Isoniazid Prevention Therapy for HIV Positive Patients Increasing Tuberculosis Prevention for HIV-Patients in Ethiopia QuickTime and a decompressor are needed to see this picture. Ashok Reddy, MD University
More informationOverview Treatment of latent TB infection Meta-analysis 36 months of IPT Screening for TB Adverse events INH Resistance IPT & ART TST Conclusions
202/03/28 Isoniazid preventive therapy: evidence for safety and efficacy Clinician s course Gavin Churchyard/ Liesl Page-Shipp 6 March 202 Overview Treatment of latent TB infection Meta-analysis 36 months
More informationDisclosures. Public Health Motivation 6/6/2012. The 12-Dose INH-Rifapentine Once-Weekly DOT Regimen: What Next?
The 12-Dose INH-Rifapentine Once-Weekly DOT Regimen: What Next? NTCA Conference June 14, 2012 John Jereb, FSEB, DTBE, CDC Special thanks to Christine Ho, Elsa Villarino, and Andrey Borisov The findings
More informationIsoniazid Preventive Therapy (IPT) in HIV-Infected and Uninfected Children. Réghana Taliep
Isoniazid Preventive Therapy (IPT) in HIV-Infected and Uninfected Children Réghana Taliep Background Tuberculosis (TB) is a common complication and leading cause of death in HIV infection HIV is the strongest
More informationTB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION
TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION Michelle Haas, M.D. Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES No relevant financial relationships OBJECTIVES
More informationTB in the Patient with HIV
TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to
More informationPediatric Tuberculosis in Los Angeles County: An Update
Pediatric Tuberculosis in Los Angeles County: An Update Julie Higashi, MD PhD Director, Tuberculosis Control Program March 2, 2019 0 Pediatricians will be the driving force of TB elimination in California
More informationIsoniazid preventive therapy for HIV+:
Isoniazid preventive therapy for HIV+: Controversial topics Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Risk of TB disease after
More informationTB Update: March 2012
TB Update: March 2012 David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Public Health 1 TB Update: March 2012 IGRAs vs TST LTBI A New Regimen NAATs What is Their
More information8/28/2017. Learning Objectives. After attending this presentation, learners will be able to:
New and Noteworthy in Tuberculosis Diagnostics and Treatment Susan Swindells, MBBS Professor of Internal Medicine University of Nebraska Medical Center Omaha, Nebraska San Antonio, Texas: August 21 to
More informationTreatment of Latent TB Infection (LTBI)
Treatment of Latent TB Infection (LTBI) Mahesh C. Patel, MD June 14, 2017 2014 MFMER slide-1 Mahesh C. Patel, MD Associate Professor Treatment of LTBI Department of Internal Medicine, Division of Infectious
More informationResearch gaps for eliminating TB deaths among people living with HIV. GJ Churchyard 25 th July 2017
Research gaps for eliminating TB deaths among people living with HIV GJ Churchyard 25 th July 2017 Overview Research gaps for preventing TB deaths among PLWHIV Programmatic management of LTBI Tests of
More informationACCESS TO MEDICINES. Update on tuberculosis field activities
ACCESS TO MEDICINES Update on tuberculosis field activities Update on clinical activities 1/3 Latent TB Prevent study (S26) main study (8053 patients) PK substudy construction of a POPPK model Paediatric
More informationTBTC research update: are we ready for 3 month treatment? 2009 TBTC Recompetition. NTCA presentation outline
TBTC research update: are we ready for 3 month treatment? Stefan Goldberg, MD Project officer, TBTC Studies 27, 28, 29 Tuberculosis Trials Consortium (TBTC) CDC Division of TB Elimination NTCA breakout
More informationDisclosures. Outline. No disclosures or conflicts of interest to report. Special LTBI situations. H t it d id ff t
Selected Topics in LTBI June 2, 2015 Bijan Ghassemieh, MD Senior Fellow UW Division of Pulmonary/Critical Care Disclosures No disclosures or conflicts of interest to report Outline Special LTBI situations
More informationApplication of New Diagnostics and Preventative Treatment in Low and High Burden Settings
Application of New Diagnostics and Preventative Treatment in Low and High Burden Settings Edward Nardell, MD Brigham & Women s Hospital Harvard Medical School Partners In Health Disclosures opps! Served
More informationCan TB Be Eliminated?
Can TB Be Eliminated? Richard E. Chaisson, MD Center for AIDS Research Center for TB Research Johns Hopkins University The Global Burden of TB -2015 All forms of TB HIV-associated TB MDR TB / RR TB Estimated
More informationTime to implement: WHO guidelines on TB Preventive Treatment
Time to implement: WHO guidelines on TB Preventive Treatment WHO End TB Strategy TARGETS: 90% reduction of deaths and 80% reduction in incidence by 2030 Early diagnosis Integrated, of TB including universal
More informationTreatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015
Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationPediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017
Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures
More informationLTBI Videos-Treatment
LTBI Videos-Treatment This program is presented by the Global Tuberculosis Institute and is based on recommendations from the Centers for Disease Control and Prevention. This is the third in a series of
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationIsoniazid Preventive Therapy (IPT)
Isoniazid Preventive Therapy (IPT) Josefina Cadorna-Carlos, M.D. Professor of Pediatrics U E R M M M C Objectives 1. Define IPT. 2. Discuss the indications for IPT. 3. Present RCT s for IPT (6H vs 9H).
More informationWHO Guidelines for IPT and ICF
WHO Guidelines for IPT and ICF Reuben Granich HIV/AIDS Department World Health Organization Haileyesus Getahun STOP TB Department World Health Organization Outline Background Evidence Recommendations Adults
More informationModeling LTBI What are the key issues to consider? Dr Dick Menzies, Montreal Chest Institute, McGill International TB Centre
Modeling LTBI What are the key issues to consider? Dr Dick Menzies, Montreal Chest Institute, McGill International TB Centre Overview The problem Treating active TB does not seem to be enough The solution:
More informationTuberculosis: Where Are We Now?
Tuberculosis: Where Are We Now? Amee Patrawalla MD MPH Rutgers - NJ Medical School Global TB Institute Rutgers, The State University of New Jersey Learning Objectives Understand the current epidemiologic
More informationClinical Trials Lecture 4: Data analysis
Clinical Trials Lecture 4: Data analysis Dick Menzies, MD Respiratory Epidemiology and Clinical Research Unit Montreal Chest Institute TB Research methods course July 17, 2014 Lecture 4: Data analysis
More informationWhat He Said: Rifampin versus Rifapentine
What He Said: Rifampin versus Rifapentine Charles A. Peloquin, Pharm.D. Director Infectious Disease Pharmacokinetics Laboratory Professor, College of Pharmacy & The Emerging Pathogens Institute University
More informationTB Nurse Case Management San Antonio, Texas April 9-11, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB / Dose Counting Rachel Munoz, RN. TB Nurse Case Manager/Nurse Consultant Austin/Travis County Health Department April 10, 2013 Rachel Munoz,
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationIssues in TB Drug Development: TB/HIV
Issues in TB Drug Development: TB/HIV Open Forum Gavin Churchyard 18 th August 2010 Presentation outline TB/HIV Epidemiology clinical aspects HIV associated TB Drug-Drug interactions Immunotherapy Latent
More informationLatent TB Infection Treatment
Latent TB Infection Treatment Douglas B. Hornick, MD Pulmonologist w/ Infectious Attitude Division of Pulmonary/Critical Care/Occ Med UI Carver College of Medicine 2014 MFMER slide-1 Disclosures: None
More informationTB Updates for the Physician Rochester, Minnesota June 19, 2009
TB Updates for the Physician Rochester, Minnesota June 19, 2009 Recent Findings & Activities of the Tuberculosis Trials Consortium (TBTC) Bill Burman Denver TBTC Unit & Denver Public Health Recent findings
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationChapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI
More informationHIV/TB Co infection TB Clinical Intensive October 11, 2018
HIV/TB Co infection TB Clinical Intensive October 11, 2018 Gabriel Chamie, MD, MPH Associate Professor of Medicine Division of HIV, Infectious Diseases & Global Medicine UCSF/San Francisco General Hospital
More informationNEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY
NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY Neil W. Schluger, M.D. Professor of Medicine, Epidemiology and Environmental Health Sciences Columbia University Global tuberculosis incidence
More informationGenomic signatures of risk of TB disease Tom Scriba, University of Cape Town
Genomic signatures of risk of TB disease Tom Scriba, University of Cape Town 2nd Expert Workshop on the development of tests for progression of LTBI to active disease 1 July 2016 Possible consequences
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationLatent tuberculosis infection
EXECUTIVE SUMMARY Latent tuberculosis infection Updated and consolidated guidelines for programmatic management Executive summary Latent tuberculosis infection (LTBI) is defined as a state of persistent
More informationDisclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None
Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division
More informationOngoing Research on LTBI and Research priorities in India
Ongoing Research on LTBI and Research priorities in India Dr. C.Padmapriyadarsini, MD, MS ICMR-National Institute for Research in Tuberculosis Chennai, India Technical Consultation Meeting on Programmatic
More informationTB Intensive San Antonio, Texas May 7-10, 2013
TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationSanta Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014
Guidelines to Revisions to the School Mandate and Requirements 1) What are the tuberculosis (TB) screening requirements for school entrance in Santa Clara County? Students must undergo a TB risk assessment
More informationAPPROACHES TO LTBI TREATMENT
APPROACHES TO LTBI TREATMENT Chris Keh, MD Director, TB Prevention and Control Program, SFDPH HS Assistant Clinical Professor, Infectious Diseases, UCSF Curry International TB Center, LTBI, June 13, 2018
More informationCommunicable Disease Control Manual Chapter 4: Tuberculosis. Assessment and Follow-Up of TB Contacts
Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Assessment and Follow-Up of TB July, 2018 Page 1 TABLE OF CONTENTS 8.0 ASSESSMENT AND
More informationTuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013
Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013 1 TB in Toronto - risk groups Diagnosis of active TB LTBI diagnosis and management Infection control 2 TB in Toronto Case
More informationRuth Moro M.D., M.P.H. Medical Epidemiologist. CDC, Division of Tuberculosis Elimination Clinical Research Branch Tuberculosis Trials Consortium
Factors Associated with Non-completion of Latent Tuberculosis Infection (LTBI) Treatment: Reasons other than Adverse Events (AE) The TB Trials Consortium PREVENT TB Study 26 Ruth Moro M.D., M.P.H. Medical
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationImproving Translation in TB Drug Development Through Quantitative Modeling. CPTR Workshop 2016, Washington DC
Improving Translation in TB Drug Development Through Quantitative Modeling Lessons from Recent Phase III TB Trials CPTR Workshop 2016, Washington DC Christian Lienhardt Global TB Programme WHO, Geneva,
More informationApproach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD
Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD Consultant, Southern N.J. Regional Chest Clinic New Jersey State TB Physician Advisory Board Cooper Univ. Hospital EIP Program TB and HIV
More informationProgrammatic management of latent TB infection: Global perspective and updates. Haileyesus Getahun, MD, MPH, PhD.
Programmatic management of latent TB infection: Global perspective and updates Haileyesus Getahun, MD, MPH, PhD. What is latent TB infection? A state of persistent immune response to stimulation by Mycobacterium
More informationINH Preventive Therapy in. Mark F Cotton KID-CRU & Division of Pediatric Infectious Diseases, TygerbergChildren s Hospital & Stellenbosch University
INH Preventive Therapy in Children Mark F Cotton KID-CRU & Division of Pediatric Infectious Diseases, TygerbergChildren s Hospital & Stellenbosch University Prophylactic effect of INH on primary TB in
More informationDiagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017
Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationTherapy for Latent Tuberculosis Infection
Screening and Treatment of LTBI in TB Control in the US Margarita Elsa Villarino MD MPH Division of TB Elimination, CDC April 14, 2004 TB Prevention and Control in the United States The fundamental strategies
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 TB in the HIV Patient Lisa Armitige, MD, PhD April 6, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests
More informationProgrammatic management of LTBI : a two pronged approach for ending the TB epidemic. Haileyesus Getahun Global TB Programme WHO/HQ
Programmatic management of LTBI : a two pronged approach for ending the TB epidemic Haileyesus Getahun Global TB Programme WHO/HQ What is latent TB infection? A state of persistent immune response to stimulation
More informationTreatment of Tuberculosis
Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict
More informationLatent TB Infection (LTBI) Strategies for Detection and Management
Latent TB Infection (LTBI) Strategies for Detection and Management Patrick T. Dowling MD,MPH Professor and Chair Dept of Family Medicine David Geffen School of Medicine at UCLA Pri-Med March 29 2014 Pdowling@mednet.ucla.edu
More informationDisclosure Informa0on Western Occupa0onal Health Conference 2012
Infec&ous Disease: Guidelines, Updates & Implementa&on in the Health Care Se=ng James Watt, MD, MPH Chief, Division of Communicable Disease Control Center for Infectious Diseases California Department
More informationCDC's Tuberculosis Trials Consortium
CDC's Tuberculosis Trials Consortium Kayla Laserson, Andrew Vernon, Erin Bliven, Neil Schluger, William Burman, Fred Gordin, Tim Sterling, Carol Dukes Hamilton, Debra Benator, Donna Conwell, Nancy Dianis,
More informationTreatment of Tuberculosis, 2017
Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,
More informationPREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal
PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.
More informationDetection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges
Detection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges David Karol, MD, MA Bureau of Prisons, FMC Butner Duke University Medical Center June 26, 2013 No Disclosures
More informationFocus on LTBI October 17, 2017
APPROACHES TO LTBI TREATMENT Chris Keh, MD Director, TB Prevention and Control Program, SFDPH HS Assistant Clinical Professor, Infectious Diseases, UCSF Curry International TB Center, LTBI, October 17,
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationA Randomized Clinical Trial Comparing 6 EH vs 36H for TB Prevention in HIV-infected Adults in south India: Impact on Mortality
A Randomized Clinical Trial Comparing 6 EH vs 36H for TB Prevention in HIV-infected Adults in south India: Impact on Mortality Soumya Swaminathan,, PA Menon,, P Venkatesan et al Indian Council of Medical
More informationDrug Interactions Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant
More informationTuberculosis Intensive November 17 20, 2015 San Antonio, TX
Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures
More informationTreatment of Tuberculosis
TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features
More informationHIV/TB. Sylvia LaCourse MD, MPH Department of Medicine, Division of Allergy & Infectious Disease. TB Clinical Intensive Seattle, WA June 16-17, 2016
HIV/TB Sylvia LaCourse MD, MPH Department of Medicine, Division of Allergy & Infectious Disease TB Clinical Intensive Seattle, WA June 16-17, 2016 Roadmap for today s talk HIV/TB Epidemiology Global US
More informationTUBERCULOSIS AND THE TNF-α INHIBITORS. Lloyd Friedman, M.D. Yale University Milford Hospital
TUBERCULOSIS AND THE TNF-α INHIBITORS Lloyd Friedman, M.D. Yale University Milford Hospital Outline TNF-α Anti-TNF-α medications Rates of tuberculosis Lower rates with etanercept Screening for latent tuberculosis
More informationDiagnosis & Management of Latent TB Infection
Diagnosis & Management of Latent TB Infection Prof. Ashok Rattan, MD, MAMS, INSA DFG, WHO Lab Director Academics, Industry: Research, Diagnosis, Public Health, Academics Adviser: Laboratory Operations,
More informationTB Infection Who is Testing and Treating? TB Control and Elimination: Current Dilemma. Span of TB Control: 2010
TB Infection Who is Testing and Treating? Jennifer Flood, M.D., M.P.H. California Department of Public Health Tuberculosis Control Branch Jennifer.Flood@cdph.ca.gov 1 TB Control and Elimination: Current
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More informationPre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:
Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global
More information11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016
Disclosures Update In Tuberculosis, Indiana 2017 Bradley Allen, MD, PhD, FACP, FIDSA Indiana University School of Medicine Division of Infectious Diseases Roudebush VAMC Indianapolis Medical Consultant,
More informationDose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016
Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016 TB Nurse Case Management September 7-9, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Jessica Quintero, M.Ed., has the following disclosures
More informationLTBI Treatment and Anti TNF alpha
LTBI Treatment and Anti TNF alpha Therapy Julie Higashi, MD PhD Director, TB Control Section San Francisco Department of Public Health TNF alpha is important for the immune response against TB Macrophages
More informationTable S1: Summary Table: Assessment of Individual Studies by Outcome
Table S1: Summary Table: Assessment of Individual Studies by Outcome Study Characteristics Citation Mortality Akolo, C., et 2010. 1 Bucher, H.C., et 1999. 2 Study Design (e.g., RCT) Country, Study Period
More informationApplication to add rifapentine to the Essential List of Medicines as a medicine for the treatment of latent tuberculosis infection
Application to add rifapentine to the Essential List of Medicines as a medicine for the treatment of latent tuberculosis infection 1 P age Table of contents Abbreviations.... page 3 Executive summary.....page
More information